Country: Իռլանդիա
language: անգլերեն
source: HPRA (Health Products Regulatory Authority)
Telmisartan; Hydrochlorothiazide
Accord Healthcare Ireland Ltd.
C09DA; C09DA07
Telmisartan; Hydrochlorothiazide
40 mg / 12.5 milligram(s)
Tablet
Angiotensin II antagonists and diuretics; telmisartan and diuretics
Marketed
2019-08-02
1 PACKAGE LEAFLET: INFORMATION FOR THE USER TELMISARTAN/HYDROCHLOROTHIAZIDE 40 MG/12.5 MG TABLETS telmisartan/hydrochlorothiazide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Telmisartan/Hydrochlorothiazide is and what it is used for 2. What you need to know before you take Telmisartan/Hydrochlorothiazide 3. How to take Telmisartan/Hydrochlorothiazide 4. Possible side effects 5. How to store Telmisartan/Hydrochlorothiazide 6. Contents of the pack and other information 1. WHAT TELMISARTAN/HYDROCHLOROTHIAZIDE IS AND WHAT IT IS USED FOR Telmisartan/Hydrochlorothiazide is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet. Both of these substances help to control high blood pressure. - Telmisartan belongs to a group of medicines called angiotensin II receptor antagonists. Angiotensin-II is a substance produced in your body which causes your blood vessels to narrow thus increasing your blood pressure. Telmisartan blocks the effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered. - Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which cause your urine output to increase, leading to a lowering of your blood pressure. High blood pressure, if not treated, can damage blood vessels in several organs, which could lead sometimes to heart attack, heart or kidney failure, stroke, or blindness. There are usually no symptoms of high blood pressure before damage occurs. Thus it is important to regularly read_full_document
Health Products Regulatory Authority 05 January 2022 CRN00CPTY Page 1 of 17 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telmisartan/Hydrochlorothiazide 40 mg/12.5 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide. Excipients with known effect: Telmisartan Hydrochlorothiazide 40 mg/12.5 mg tablets: Each tablet contains 0.74 mg of sodium For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. Telmisartan Hydrochlorothiazide 40 mg/12.5 mg tablets are white or almost white, 6.55 x 13.6 mm oval‑shaped and biconvex tablets marked with TH on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of essential hypertension. Telmisartan Hydrochlorothiazide fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Telmisartan Hydrochlorothiazide should be taken in patients whose blood pressure is not adequately controlled by telmisartan alone. Individual dose titration with each of the two components is recommended before changing to the fixed dose combination. When clinically appropriate, direct change from monotherapy to the fixed combination may be considered. - Telmisartan Hydrochlorothiazide 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 40 mg. _Special populations:_ _Patients with renal impairment_ Periodic monitoring of renal function is advised (see section 4.4). _Patients with hepatic impairment_ In patients with mild to moderate hepatic impairment the posology should not exceed Telmisartan Hydrochlorothiazide 40 mg/12.5 mg once daily. Telmisartan Hydrochlorothiazide is not indicated in patients with severe hepatic impairment. Thiazides should be used with caution in patients with impaired hepatic function (see section 4.4). _Elderly patients_ No d read_full_document